RLYB vs. JAGX, HOOK, TPST, ASMB, SCYX, VTVT, MRNS, IFRX, SLS, and AFMD
Should you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Jaguar Health (JAGX), Hookipa Pharma (HOOK), Tempest Therapeutics (TPST), Assembly Biosciences (ASMB), SCYNEXIS (SCYX), vTv Therapeutics (VTVT), Marinus Pharmaceuticals (MRNS), InflaRx (IFRX), SELLAS Life Sciences Group (SLS), and Affimed (AFMD). These companies are all part of the "pharmaceutical preparations" industry.
Jaguar Health (NASDAQ:JAGX) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings.
In the previous week, Jaguar Health had 1 more articles in the media than Rallybio. MarketBeat recorded 8 mentions for Jaguar Health and 7 mentions for Rallybio. Rallybio's average media sentiment score of 0.14 beat Jaguar Health's score of 0.13 indicating that Jaguar Health is being referred to more favorably in the media.
12.0% of Jaguar Health shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 0.2% of Jaguar Health shares are held by insiders. Comparatively, 7.4% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Jaguar Health has higher revenue and earnings than Rallybio.
Rallybio has a net margin of 0.00% compared to Rallybio's net margin of -377.95%. Jaguar Health's return on equity of -66.59% beat Rallybio's return on equity.
Jaguar Health has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.63, indicating that its stock price is 263% less volatile than the S&P 500.
Rallybio has a consensus target price of $12.20, indicating a potential upside of 589.27%. Given Jaguar Health's higher possible upside, analysts plainly believe Rallybio is more favorable than Jaguar Health.
Jaguar Health received 1802 more outperform votes than Rallybio when rated by MarketBeat users. Likewise, 89.08% of users gave Jaguar Health an outperform vote while only 73.33% of users gave Rallybio an outperform vote.
Summary
Jaguar Health and Rallybio tied by winning 7 of the 14 factors compared between the two stocks.
Get Rallybio News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rallybio Competitors List
Related Companies and Tools
